on AMOEBA (EPA:ALMIB)
Amoéba Expands Production to Support AXPERA's Market Launch
Amoéba, a French industrial greentech firm, is extending production capacity at its Chassieu site. This move supports the commercial deployment of their "AXPERA" biocontrol products. The decision follows a memorandum signed with Koppert in 2024, aimed at securing a global contract by May 2025. Recent positive conclusions from the European Food Safety Authority (EFSA) have also paved the way for marketing authorizations expected this year.
The extension involves a €1.1 million investment to increase production and reduce costs through technical improvements. Additionally, Amoéba is exploring further capacity expansions, including partnerships with CDMOs and Koppert. These strategies aim to optimize production for AXPERA's commercial launch, aligning with expected volume increases and cost efficiencies.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all AMOEBA news